Cerveau tapped for Alzheimer's research

By Melissa Fassbender contact

- Last updated on GMT

Cerveau tapped for Alzheimer's research

Related tags: Positron emission tomography

Cerveau has signed a research agreement through which it will supply its early-stage imaging agent to assess the stages of Alzheimer’s disease and other neurodegenerative diseases.

Cerveau Technologies, Inc. will support various research projects as part of the clinical research agreement with the NIH-funded University of Wisconsin-Madison Alzheimer’s Disease Research Center (ADRC)

The agreement specifically incudes access to the company’s imaging agent, MK-6240, which it licensed from Merk & CO Inc​ (MSD) in January of this year.

The agent will be used in Positron Emission Tomography (PET) scans to evaluate the progression of neurofibrillary tangles (NFTs) in the brain.

Dr. Sterling Johnson, Associate Director of the Wisconsin Alzheimer’s Disease Research Center commented in a release that the collaborative tau imaging research program will provide “valuable information about the rates of progression across the Alzheimer’s Disease stages from preclinical to overt dementia​.”

(Feature image: iStock/semakokal)

Related topics: Preclinical Research, Preclinical

Related news

Show more

Related products

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

Related suppliers

Follow us

Featured Events

View more


View more